Possible Increased Risk of Death With Lymphoma Drug: FDA Possible Increased Risk of Death With Lymphoma Drug: FDA

The FDA has issued a drug safety communication about umbralisib after initial results from a phase 3 trial suggested an elevated mortality risk in patients receiving the oral agent.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news